Saniona targets late — October FDA IND filing for SAN2465 ahead of Phase 1 trial in healthy volunteers
Saniona released new preclinical evidence supporting SAN2465 as a potential rapid-acting oral antidepressant; results were presented in this announcement. The studies showed improved measures of brain synaptic function, reinforcing earlier animal findings of rapid, sustained antidepressant-like effects. Saniona is prep